IOL Chemicals and Pharmaceuticals Limited (BOM: 524164)
India
· Delayed Price · Currency is INR 484.30
+4.60 (0.96%)
At close: Sep 10, 2024
IOL Chemicals and Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 20,720 | 21,328 | 22,171 | 21,840 | 19,670 | 18,945 | Upgrade
|
| Revenue Growth (YoY) | -6.47% | -3.80% | 1.52% | 11.03% | 3.83% | 12.41% | Upgrade
|
| Cost of Revenue | 13,899 | 14,185 | 15,605 | 15,812 | 11,096 | 10,737 | Upgrade
|
| Gross Profit | 6,821 | 7,143 | 6,566 | 6,028 | 8,573 | 8,207 | Upgrade
|
| Selling, General & Admin | 2,017 | 2,027 | 1,686 | 1,415 | 1,157 | 973.5 | Upgrade
|
| Other Operating Expenses | 2,712 | 2,810 | 2,617 | 2,019 | 1,497 | 1,495 | Upgrade
|
| Operating Expenses | 5,382 | 5,466 | 4,765 | 3,867 | 3,043 | 2,826 | Upgrade
|
| Operating Income | 1,439 | 1,677 | 1,801 | 2,161 | 5,531 | 5,382 | Upgrade
|
| Interest Expense | -90.4 | -108.4 | -106.9 | -24.3 | -9.4 | -160.1 | Upgrade
|
| Interest & Investment Income | 139.9 | 139.9 | 167.3 | 182 | 159.9 | 52.5 | Upgrade
|
| Currency Exchange Gain (Loss) | 130.8 | 130.8 | 70.6 | 104.4 | 69.1 | 92.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -25.4 | -28.6 | -42.2 | -25.1 | -39.9 | -38.2 | Upgrade
|
| EBT Excluding Unusual Items | 1,594 | 1,811 | 1,890 | 2,398 | 5,710 | 5,328 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.5 | 3.5 | 2.3 | 0.2 | 0.1 | -0.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.4 | 1.4 | -3.3 | -2.4 | 0.5 | - | Upgrade
|
| Asset Writedown | -0.4 | -0.4 | -2.6 | -8.5 | -1.5 | - | Upgrade
|
| Other Unusual Items | 1.1 | 1.1 | 0.3 | -139 | 4.4 | 4.5 | Upgrade
|
| Pretax Income | 1,600 | 1,817 | 1,887 | 2,249 | 5,714 | 5,332 | Upgrade
|
| Income Tax Expense | 414.5 | 472.2 | 495.1 | 571.8 | 1,268 | 1,720 | Upgrade
|
| Net Income | 1,185 | 1,344 | 1,391 | 1,677 | 4,446 | 3,613 | Upgrade
|
| Net Income to Common | 1,185 | 1,344 | 1,391 | 1,677 | 4,446 | 3,613 | Upgrade
|
| Net Income Growth | -21.15% | -3.39% | -17.02% | -62.28% | 23.05% | 52.64% | Upgrade
|
| Shares Outstanding (Basic) | 59 | 59 | 59 | 59 | 58 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 59 | 59 | 59 | 58 | 57 | Upgrade
|
| Shares Change (YoY) | -0.05% | - | - | 0.64% | 2.32% | 1.42% | Upgrade
|
| EPS (Basic) | 20.20 | 22.90 | 23.70 | 28.56 | 76.21 | 63.51 | Upgrade
|
| EPS (Diluted) | 20.20 | 22.90 | 23.70 | 28.56 | 76.21 | 63.38 | Upgrade
|
| EPS Growth | -21.10% | -3.38% | -17.02% | -62.52% | 20.24% | 50.51% | Upgrade
|
| Free Cash Flow | - | 159.1 | -895.5 | -602.4 | 2,716 | 3,905 | Upgrade
|
| Free Cash Flow Per Share | - | 2.71 | -15.25 | -10.26 | 46.56 | 68.50 | Upgrade
|
| Dividend Per Share | - | 5.000 | 4.000 | 4.000 | 6.000 | 3.000 | Upgrade
|
| Dividend Growth | - | 25.00% | 0% | -33.33% | 100.00% | - | Upgrade
|
| Gross Margin | 32.92% | 33.49% | 29.61% | 27.60% | 43.59% | 43.32% | Upgrade
|
| Operating Margin | 6.95% | 7.86% | 8.12% | 9.90% | 28.12% | 28.41% | Upgrade
|
| Profit Margin | 5.72% | 6.30% | 6.28% | 7.68% | 22.60% | 19.07% | Upgrade
|
| Free Cash Flow Margin | - | 0.75% | -4.04% | -2.76% | 13.81% | 20.61% | Upgrade
|
| EBITDA | 2,099 | 2,295 | 2,253 | 2,584 | 5,910 | 5,729 | Upgrade
|
| EBITDA Margin | 10.13% | 10.76% | 10.16% | 11.83% | 30.05% | 30.24% | Upgrade
|
| D&A For EBITDA | 659.2 | 617.8 | 452.2 | 422.8 | 379.4 | 347.3 | Upgrade
|
| EBIT | 1,439 | 1,677 | 1,801 | 2,161 | 5,531 | 5,382 | Upgrade
|
| EBIT Margin | 6.95% | 7.86% | 8.12% | 9.90% | 28.12% | 28.41% | Upgrade
|
| Effective Tax Rate | 25.91% | 26.00% | 26.24% | 25.43% | 22.20% | 32.25% | Upgrade
|
| Revenue as Reported | 21,024 | 21,629 | 22,427 | 22,161 | 19,913 | 19,105 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.